文献速递主动脉疾病

血管紧张素调节药物对胸主动脉瘤TEVAR结局的影响

The impact of angiotensin-modulating medications on outcomes of thoracic endovascular aortic repair in patients with thoracic aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2025-10-09

本研究基于Vascular Quality Initiative数据库,纳入2014年1月至2024年期间因胸主动脉瘤行TEVAR的7839例患者,比较术前使用ACEI/ARB与未使用者的结局。结果显示两组30天和1年死亡率无差异,但术前使用ACEI/ARB与更高的当日拔管率(OR 1.38)和更低的延长住院风险(OR 0.88)独立相关。

要点

  • 术前使用ACEI/ARB与TEVAR后30天及1年死亡率无显著差异。
  • 术前使用ACEI/ARB独立 associated with 更高当日拔管率(OR 1.38)。
  • 术前使用ACEI/ARB独立 associated with 更低延长住院风险(OR 0.88)。

核心结论

  • 术前使用ACEI/ARB与TEVAR后当日拔管率更高和住院时间更短独立相关,且不增加30天或1年死亡率。
  • 研究提示TEVAR患者可继续使用ACEI/ARB。

研究设计与样本

  • 回顾性多中心队列研究,查询Vascular Quality Initiative数据库2014年1月至2024年数据。
  • 纳入因胸主动脉瘤行TEVAR的患者,排除年龄<18岁、结缔组织病及需进一步开胸者,最终分析7839例。
  • 主要结局为30天和1年死亡率,次要结局包括术后心肌梗死、心律失常、红细胞输注量、当日拔管和延长住院。
  • 采用多变量logistic回归分析短期结局,Kaplan-Meier生存分析和log-rank检验分析1年生存率。

主要发现

  • 术前使用ACEI/ARB组男性、非黑人、高血压、糖尿病、充血性心力衰竭、冠心病史、肾功能不全及术前功能状态较好的比例更高。
  • 两组30天和1年死亡率相似(所有P > .05)。
  • 术后心肌梗死、红细胞输注或心律失常发生率无显著差异。
  • 术前ACEI/ARB使用与更高当日拔管几率独立相关(OR 1.38,95%CI 1.07-1.77,P = .014)。
  • 术前ACEI/ARB使用与更低延长住院风险独立相关(OR 0.88,95%CI 0.80-0.97,P = .010)。

临床怎么用

  • 对于因胸主动脉瘤行TEVAR的患者,术前可考虑继续使用ACEI/ARB,不因担心术后并发症而常规停药。
  • 术前ACEI/ARB使用可能有助于提高当日拔管率并缩短住院时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Withholding renin-angiotensin-aldosterone system antagonists before surgery has been suggested in previous studies on nonvascular procedures owing to their potential contribution to postoperative comorbidities. Evidence on the role of renin-angiotensin-aldosterone system modulation is limited in vascular surgery literature. This study investigates the impact of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on outcomes of thoracic endovascular aortic repair (TEVAR) in patients with thoracic aortic aneurysms. METHODS: The Vascular Quality Initiative database was queried for all patients who underwent TEVAR for thoracic aortic aneurysm between January 2014 and 2024. Patients aged <18 years and those with connective tissue disorders were excluded. Patients who required further open thoracotomy were also excluded from the analysis. Our primary outcomes were 30-day and 1-year mortality. Our secondary outcomes were postoperative myocardial infarction, dysrhythmia, number of packed red blood cell transfusions needed, same-day extubation, and prolonged length of hospital stay. Multivariate logistic regression analyzed short-term outcomes and Kaplan-Meier survival, and the log-rank test analyzed 1-year survival rates. RESULTS: Among 7839 eligible patients, those receiving preoperative ACEI/ARB were more likely to be male, non-Black, hypertensive, and diabetic and to have congestive heart failure, a history of coronary artery disease, some degree of kidney dysfunction, and better preoperative functional status. The 30-day and 1-year mortality rates were similar between groups (all P > .05). There were no significant differences in rates of postoperative myocardial infarction, packed red blood cell transfusion, or dysrhythmia. However, preoperative ACEI/ARB use was independently associated with higher odds of same-day extubation (OR, 1.38; 95% confidence interval, 1.07-1.77; P = .014) and a lower risk of prolonged hospital stay (OR, 0.88; 95% confidence interval, 0.80-0.97; P = .010). CONCLUSIONS: Despite several previous studies reporting adverse effects of preoperative ACEI/ARBs on surgical outcomes, this multi-institutional study found that patients receiving ACEI/ARBs preoperatively were more likely to be extubated on the day of the operation and had shorter hospital lengths of stay. There were no differences in other postoperative outcomes or survival up to 1 year. This study suggests continuing the use of ACEI/ARBs in patients undergoing TEVAR.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Nakhaei P, Luu IY, Abdelkarim A, et al. The impact of angiotensin-modulating medications on outcomes of thoracic endovascular aortic repair in patients with thoracic aortic aneurysms. J Vasc Surg. 2025. PMID: 41067582. doi:10.1016/j.jvs.2025.09.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。